The United States has included India among the eligible jurisdictions for a zero per cent tariff on specified specialty pharmaceutical products and ingredients, providing targeted relief to Indian drug manufacturers. This policy adjustment coincides with Washington’s implementation of a 100 per cent tariff on certain patented pharmaceutical imports for covered companies. Published by the US Commerce Department, the new tariff provisions take effect for covered companies not previously subject to the measure.
Eligible Specialized Products and Framework:
The zero per cent tariff exemption does not apply to all pharmaceutical goods shipped from India; rather, it is restricted to specific medicines and ingredients outlined in an April presidential proclamation. Eligible categories include:
Orphan drugs, nuclear medicines, and plasma-derived therapies.
Cell therapies, gene therapies, and antibody-drug conjugates.
Medical countermeasures addressing chemical, biological, radiological, and nuclear threats, alongside selected animal-health products.
India shares this zero-tariff eligibility status with 19 other nations including the European Union, Japan, South Korea, Britain, and Taiwan because these jurisdictions maintain current or upcoming trade and security framework agreements with the United States.
Distinction Between Patented and Generic Exports:
These exemptions stem from President Donald Trump’s April proclamation under Section 232 of the Trade Expansion Act, which adjusted pharmaceutical imports to encourage domestic production. While patented products face the 100 per cent duty, generic pharmaceutical products and their associated ingredients remain exempt from Section 232 pharmaceutical tariffs entirely. This distinction is vital for India, a major global supplier of generic medicines to the United States, while simultaneously offering a defined pathway for Indian manufacturers of specialized and patented therapies to retain competitive, zero-tariff market access.
